• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

    5/30/25 7:00:00 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNAC alert in real time by email

    FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG).

    Descartes-08, Cartesian's lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors.

    "With the first participant now successfully enrolled, commencement of our Phase 3 AURORA trial represents a significant milestone in our mission to deliver a differentiated, durable treatment option to patients with MG," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "With sustained benefits observed through 12 months in our Phase 2b trial, we believe Descartes-08 has the potential to transform the current MG treatment paradigm with just a single course of therapy."

    "Marked by chronic use of steroids and other immunosuppressants while often delivering only limited efficacy, the current standard of care for patients with MG is inadequate," said James (Chip) F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and Allied Health at the University of North Carolina School of Medicine. "Supported by compelling results from the Phase 2b trial, I firmly believe that Descartes-08 has the potential to serve as a safe, flexible, and durable treatment option for patients with MG. I look forward to helping advance this important study."

    The Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive (AChR Ab+) MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo.

    In April 2025, the Company announced updated efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with MG. After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in the MG-ADL score at Month 12. The deepest and most compelling sustained responses were observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12. The safety profile of Descartes-08 was consistent with previously reported data and continues to support outpatient administration.

    About Cartesian Therapeutics

    Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

    Forward Looking Statements

    Any statements in this press release about the future expectations, plans and prospects of the Company, including without limitation, statements regarding observations and data from the Company's clinical trials, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the ability of the Company's product candidates to be administered in an outpatient setting or without the need for preconditioning lymphodepleting chemotherapy, the potential of Descartes-08, Descartes-15, or any of the Company's other product candidates to treat myasthenia gravis, systemic lupus erythematosus, juvenile dermatomyositis, multiple myeloma, or any other disease, the anticipated timing or the outcome of the FDA's review of the Company's regulatory filings, the Company's ability to conduct its clinical trials and preclinical studies, the timing or making of any regulatory filings, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, and enrollment in the Company's clinical trials and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "hypothesize," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial, whether results of early clinical trials will be indicative of the results of later clinical trials, and whether results observed in certain patient subgroups will be indicative of the results in such subgroups in later clinical trials or are reflective of a product candidate's overall characteristics, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company's technology, potential delays in enrollment of patients, undesirable side effects of the Company's product candidates, its reliance on third parties to conduct its clinical trials, the Company's inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company's recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company's common stock, risks related to geopolitical conflicts and pandemics and other important factors discussed in the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward looking statements included in this press release, except as required by law.

    Contact Information:

    Investor Contact:

    Megan LeDuc

    Associate Director, Investor Relations

    [email protected]

    Media Contact:

    David Rosen

    Argot Partners

    [email protected]



    Primary Logo

    Get the next $RNAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNAC

    DatePrice TargetRatingAnalyst
    12/19/2024$42.00Buy
    BTIG Research
    8/6/2024Buy
    TD Cowen
    7/2/2024Outperform → Perform
    Oppenheimer
    6/4/2024$50.00Outperform
    Oppenheimer
    5/24/2024$40.00Buy
    Mizuho
    4/23/2024$2.00 → $54.00Buy
    H.C. Wainwright
    4/23/2024$39.00Outperform
    Leerink Partners
    More analyst ratings

    $RNAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Cartesian Therapeutics with a new price target

      BTIG Research initiated coverage of Cartesian Therapeutics with a rating of Buy and set a new price target of $42.00

      12/19/24 8:25:53 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Cartesian Therapeutics

      TD Cowen initiated coverage of Cartesian Therapeutics with a rating of Buy

      8/6/24 6:25:49 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Cartesian Therapeutics from Outperform to Perform

      7/2/24 11:30:39 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNAC
    SEC Filings

    See more
    • Cartesian Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      5/30/25 7:02:49 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Cartesian Therapeutics Inc.

      S-8 - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      5/8/25 7:13:14 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cartesian Therapeutics Inc.

      10-Q - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      5/8/25 7:05:43 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartesian Therapeutics Announces New Employment Inducement Grants

      FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's common stock with an exercise price of $9.98, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company

      6/3/25 7:05:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

      FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG). Descartes-08, Cartesian's lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors.

      5/30/25 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

      FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company's website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time. About Cartesian Therapeutics Cartesian Therapeutics is a

      5/13/25 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

      SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      11/18/24 9:44:37 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

      SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      10/15/24 4:30:56 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

      SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      10/4/24 6:08:15 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operations Officer English Emily exercised 7,500 units of Common Stock at a strike of $3.30, increasing direct ownership by 16% to 55,226 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      5/14/25 4:15:52 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operations Officer English Emily exercised 7,500 units of Common Stock at a strike of $3.30, increasing direct ownership by 19% to 47,726 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      4/16/25 4:35:51 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $1,522,517 worth of shares (149,075 units at $10.21), increasing direct ownership by 0.26% to 8,643,685 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      4/11/25 5:29:40 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNAC
    Leadership Updates

    Live Leadership Updates

    See more
    • Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients with myasthenia gravis expected by year-end Dosing underway in Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $220.9M of cash, cash equivalents, and restricted cash as of September 30, 2024 expected to support planned operations, including completion of planned Phase

      11/7/24 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

      Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis; End-of-Phase 2 meeting with FDA expected by year-end Dosed first SLE patient in Phase 2 trial of Descartes-08 IND filing for pediatric basket study of Descartes-08 with focus in neurology and rheumatology expected by year-end PIPE financing strengthened balance sheet, with net proceeds expected to support development of Descartes-08 in MG through planned Phase 3 trial GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today rep

      8/8/24 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

      GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced the appointment of Kemal Malik, MBBS to its Board of Directors. Dr. Malik brings to Cartesian over 30 years of global development, regulatory, and commercial expertise at leading pharmaceutical organizations. "We are thrilled to welcome Dr. Malik, a proven leader and industry veteran, to our Board of Directors," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "His deep experience in successfully advancing innovative therapies through all st

      7/2/24 4:05:00 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNAC
    Financials

    Live finance-specific insights

    See more
    • Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

      Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo Deepening responses observed over time in Phase 2b trial, with Descartes-08-treated participants observed to have a 5.5-point reduction in MG-ADL at Month 4 Durable responses observed through Month 12 in Phase 2b trial Safety profile consistent with previously reported data and continues to support outpatient administration Company to host conference call and webcast with key opinion leader today at 7:30 a.m. ET FREDERICK, Md., Dec. 03, 2024 (GLOB

      12/3/24 6:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

      FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that updated efficacy and safety data from the Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis will be presented at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, being held December 2-4, 2024 in Philadelphia. Details of the presentation are as follows: Title: Perspectives on Bringing Cell Therapies to the Autoimmune Space: From Concept to ClinicSession Name: Diving into Challenges & Successes in the Autoimmune Space to Direct Futu

      11/21/24 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

      Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo Deep and durable responses up to at least six months observed in patients treated with Descartes-08 Safety profile continues to support outpatient administration Company expects to hold End-of-Phase 2 meeting with the FDA by year-end Company to host conference call today at 8:00 a.m. ET GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneerin

      7/2/24 6:30:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Springer Timothy A bought $1,522,517 worth of shares (149,075 units at $10.21), increasing direct ownership by 0.26% to 8,643,685 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      4/11/25 5:29:40 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $1,371,154 worth of shares (89,863 units at $15.26), increasing direct ownership by 1% to 8,621,325 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      3/20/25 7:50:25 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $366,354 worth of shares (20,967 units at $17.47), increasing direct ownership by 0.25% to 8,531,462 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/15/25 4:08:27 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care